{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-004258","form_type":"8-K","ticker":"ACTU","cik":"0001652935","company_name":"ACTUATE THERAPEUTICS, INC.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.213538+00:00","generated_at":"2026-05-19T22:07:41.860682+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Actuate Therapeutics presents Phase 2 elraglusib data showing overall survival benefit in pancreatic cancer","bullets":["Phase 2 (Actuate-1801 Part 3B) data of elraglusib with gemcitabine/nab-paclitaxel showed overall survival benefit in first-line metastatic pancreatic cancer.","KOL event featured four GI oncology experts who discussed elraglusib's mechanism targeting EMT, NF-kB, and immune activation.","Dr. Colin Weekes stated elraglusib is the first drug in years to improve outcomes on standard chemotherapy backbones.","Drug was well-tolerated; neutropenia occurred but no febrile neutropenia; transient vision changes resolved within 24 hours.","Study PI Dr. Deva Mahalingam highlighted unique GSK-3 beta inhibition and survival curve separation in a challenging patient population."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-004258","json":"https://secwatch.observer/filing/0001683168-25-004258.json","markdown":"https://secwatch.observer/filing/0001683168-25-004258.md","text":"https://secwatch.observer/filing/0001683168-25-004258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825004258/0001683168-25-004258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652935/000168316825004258/actuate_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-19T22:07:41.860682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}